Dong C, Liu L, Qiao Y, Wang M, et al. First-line envafolimab plus recombinant human-endostatin in advanced non-small cell lung cancer with PD-L1 tumor proportion score >/=1% (Endouble): A multicenter, prospective, single-arm, phase 2 trial. Cancer 2026;132:e70479.
PMID: 42216493